

Charlotte E Teunissen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4340247/publications.pdf>

Version: 2024-02-01

564
papers

27,807
citations

7087

78
h-index

9854

141
g-index

635
all docs

635
docs citations

635
times ranked

23201
citing authors

#	ARTICLE	IF	CITATIONS
1	Nutritional Status Is Associated With Clinical Progression in Alzheimer's Disease: The NUDAD Project. <i>Journal of the American Medical Directors Association</i> , 2023, 24, 638-644.e1.	1.2	10
2	NT-proBNP and sRAGE levels in early rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2023, 52, 243-249.	0.6	2
3	Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiology. <i>Alzheimer's and Dementia</i> , 2023, 19, 807-820.	0.4	4
4	Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 102-110.	1.4	13
5	Use of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in A Tertiary Care Memory Clinic. <i>Canadian Journal of Neurological Sciences</i> , 2022, 49, 203-209.	0.3	5
6	State of the art of lumbar puncture and its place in the journey of patients with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 159-177.	0.4	33
7	Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma A β ²⁴² /A β ²⁴⁰ and p-tau. <i>Alzheimer's and Dementia</i> , 2022, 18, 283-293.	0.4	72
8	The natural history of primary progressive aphasia: beyond aphasia. <i>Journal of Neurology</i> , 2022, 269, 1375-1385.	1.8	23
9	Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1121-1125.	1.4	34
10	Neurofilament light chain and glial fibrillary acidic protein levels in metachromatic leukodystrophy. <i>Brain</i> , 2022, 145, 105-118.	3.7	18
11	The wearing-off phenomenon of ocrelizumab in patients with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103364.	0.9	5
12	Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. <i>Lancet Neurology</i> , The, 2022, 21, 66-77.	4.9	360
13	Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. <i>Alzheimer's and Dementia</i> , 2022, 18, 1484-1497.	0.4	84
14	CSF Neurofilament Light Chain Concentrations Predict Outcome in Bacterial Meningitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	10
15	Associating Alzheimer's disease pathology with its cerebrospinal fluid biomarkers. <i>Brain</i> , 2022, 145, 4056-4064.	3.7	19
16	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	4.5	97
17	Association of the ATN Research Framework With Clinical Profile, Cognitive Decline, and Mortality in Patients With Dementia With Lewy Bodies. <i>Neurology</i> , 2022, 98, .	1.5	10
18	Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimer's disease. <i>Neuron</i> , 2022, 110, 1009-1022.e4.	3.8	27

#	ARTICLE	IF	CITATIONS
19	Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline. <i>Neurology</i> , 2022, 98, .	1.5	41
20	Grey matter network markers identify individuals with prodromal Alzheimer's disease who will show rapid clinical decline. <i>Brain Communications</i> , 2022, 4, fca026.	1.5	4
21	CSF proteomic signature predicts progression to Alzheimer's disease dementia. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, e12240.	1.8	3
22	Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson's disease. <i>Journal of Neuroinflammation</i> , 2022, 19, 50.	3.1	26
23	Serum neurofilament light chain, contactin-1 and complement activation in anti-MAG IgM paraprotein-related peripheral neuropathy. <i>Journal of Neurology</i> , 2022, 269, 3700-3705.	1.8	8
24	New developments of biofluid-based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2022, 18, 2292-2307.	0.4	14
25	Exercise-induced increase in blood-based brain-derived neurotrophic factor (BDNF) in people with multiple sclerosis: A systematic review and meta-analysis of exercise intervention trials. <i>PLoS ONE</i> , 2022, 17, e0264557.	1.1	19
26	Plasma Neurofilament Light Is Not Associated with Ongoing Neuroaxonal Injury or Cognitive Decline in Perinatally HIV Infected Adolescents: A Brief Report. <i>Viruses</i> , 2022, 14, 671.	1.5	2
27	Neurofilament Light Chain Levels in Multiple Sclerosis Correlate With Lesions Containing Foamy Macrophages and With Acute Axonal Damage. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .	3.1	17
28	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2022, 17, 27.	4.4	30
29	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 840651.	1.7	20
30	Association of Education and Intracranial Volume With Cognitive Trajectories and Mortality Rates Across the Alzheimer Disease Continuum. <i>Neurology</i> , 2022, 98, .	1.5	17
31	Author Response: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis. <i>Neurology</i> , 2022, 98, 471-471.	1.5	0
32	Pre-analytical stability of serum biomarkers for neurological disease: neurofilament-light, glial fibrillary acidic protein and contactin-1. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 842-850.	1.4	22
33	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2022, 18, 1868-1879.	0.4	26
34	Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies. <i>Clinical Cancer Research</i> , 2022, 28, 1572-1585.	3.2	36
35	Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12314.	1.2	15
36	Effects of age, amyloid, sex, and <i>APOE</i> ϵ 4 on the CSF proteome in normal cognition. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12286.	1.2	4

#	ARTICLE	IF	CITATIONS
37	miR-150-5p and let-7b-5p in Blood Myeloid Extracellular Vesicles Track Cognitive Symptoms in Patients with Multiple Sclerosis. <i>Cells</i> , 2022, 11, 1551.	1.8	8
38	Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .	1.2	28
39	Subjective cognitive decline and self-reported sleep problems: The SCIENCE project. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .	1.2	5
40	Determining the Minimal Important Change of Everyday Functioning in Dementia. <i>Neurology</i> , 2022, 99, .	1.5	2
41	A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging. <i>Neurology</i> , 2022, 99, .	1.5	8
42	Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 849-857.	0.9	7
43	A Novel Neurofilament Light Chain ELISA Validated in Patients with Alzheimer's Disease, Frontotemporal Dementia, and Subjective Cognitive Decline, and the Evaluation of Candidate Proteins for Immunoassay Calibration. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7221.	1.8	11
44	P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	5
45	Apolipoprotein L1 is increased in frontotemporal lobar degeneration post-mortem brain but not in ante-mortem cerebrospinal fluid. <i>Neurobiology of Disease</i> , 2022, 172, 105813.	2.1	3
46	Effect of driving speed on target visibility under mesopic conditions using a driving simulator. <i>Lighting Research and Technology</i> , 2021, 53, 231-248.	1.2	4
47	Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	19
48	Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer's Disease. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 426-438.	1.2	30
49	Variations in consecutive serum neurofilament light levels in healthy controls and multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 47, 102666.	0.9	19
50	Circulating metabolites are associated with brain atrophy and white matter hyperintensities. <i>Alzheimer's and Dementia</i> , 2021, 17, 205-214.	0.4	17
51	Lumbar puncture patient video increases knowledge and reduces uncertainty: An RCT. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12127.	1.8	5
52	Risk of dementia in APOE ϵ 4 carriers is mitigated by a polygenic risk score. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12229.	1.2	16
53	Concatenating plasma p-tau to Alzheimer's disease. <i>Brain</i> , 2021, 144, 14-17.	3.7	6
54	Biomarker testing in MCI patients—deciding who to test. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 14.	3.0	6

#	ARTICLE	IF	CITATIONS
55	Four subgroups based on tau levels in Alzheimer's disease observed in two independent cohorts. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 2.	3.0	18
56	CSF synuclein evokes NLRP3 inflammasome-mediated IL-1 β secretion from primary human microglia. <i>Glia</i> , 2021, 69, 1413-1428.	2.5	58
57	Pre-Analytical Processing and Biobanking Protocol for CSF Samples. <i>NeuroMethods</i> , 2021, , 137-145.	0.2	0
58	Targeting hippocampal hyperactivity with real-time fMRI neurofeedback: protocol of a single-blind randomized controlled trial in mild cognitive impairment. <i>BMC Psychiatry</i> , 2021, 21, 87.	1.1	8
59	Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic review and meta-analysis. <i>Reviews in the Neurosciences</i> , 2021, 32, 573-595.	1.4	38
60	Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEVELOP design and baseline results. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 53.	3.0	21
61	Cerebrospinal fluid N-224 tau helps discriminate Alzheimer's disease from subjective cognitive decline and other dementias. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 38.	3.0	12
62	Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. <i>The Lancet Healthy Longevity</i> , 2021, 2, e87-e95.	2.0	85
63	Plasma Amyloid-Beta Levels in a Pre-Symptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy Pedigree: A Cross-Sectional and Longitudinal Investigation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2931.	1.8	10
64	Preanalytical Stability of CSF Total and Oligomeric Alpha-Synuclein. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 638718.	1.7	8
65	The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau. <i>Alzheimer's and Dementia</i> , 2021, 17, 1575-1582.	0.4	51
66	Replication study of plasma proteins relating to Alzheimer's pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, 1452-1464.	0.4	13
67	Onset of Preclinical Alzheimer Disease in Monozygotic Twins. <i>Annals of Neurology</i> , 2021, 89, 987-1000.	2.8	20
68	Tissue Transglutaminase Expression Associates With Progression of Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	4
69	Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110138.	0.5	10
70	Alzheimer's disease. <i>Lancet, The</i> , 2021, 397, 1577-1590.	6.3	1,530
71	Ultrasensitive immunoassay allows measurement of serum neurofilament heavy in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 50, 102840.	0.9	5
72	Clinical Phenotypes of Behavioral Variant Frontotemporal Dementia by Age at Onset. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 381-390.	1.2	8

#	ARTICLE	IF	CITATIONS
73	A neurologist's perspective on serum neurofilament light in the memory clinic: a prospective implementation study. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 101.	3.0	17
74	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. <i>Alzheimer's and Dementia</i> , 2021, 17, 1628-1640.	0.4	23
75	Highly specific and ultrasensitive plasma test detects Abeta(1-42) and Abeta(1-40) in Alzheimer's disease. <i>Scientific Reports</i> , 2021, 11, 9736.	1.6	49
76	The plasma peptides of Alzheimer's disease. <i>Clinical Proteomics</i> , 2021, 18, 17.	1.1	18
77	Diagnostic Value of the CSF \pm -Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies. <i>Neurology</i> , 2021, 97, e930-e940.	1.5	51
78	Plasma amyloid- β oligomerization assay as a pre-screening test for amyloid status. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 133.	3.0	19
79	Serum Contactin-1 in CIDP. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, e1040.	3.1	6
80	Plasma GFAP is an early marker of amyloid- β but not tau pathology in Alzheimer's disease. <i>Brain</i> , 2021, 144, 3505-3516.	3.7	198
81	CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. <i>Proteomes</i> , 2021, 9, 36.	1.7	9
82	Genetics Contributes to Concomitant Pathology and Clinical Presentation in Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 269-279.	1.2	10
83	Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum. <i>Neurology</i> , 2021, 97, e1276-e1287.	1.5	44
84	Head-to-Head Comparison of 8 Plasma Amyloid- β 42/40 Assays in Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 1375.	4.5	195
85	Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e1898-e1905.	1.5	32
86	Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals. <i>Brain Communications</i> , 2021, 3, fcab201.	1.5	14
87	Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. <i>Lancet Neurology</i> , The, 2021, 20, 739-752.	4.9	220
88	A Cystatin C Cleavage ELISA Assay as a Quality Control Tool for Determining Sub-Optimal Storage Conditions of Cerebrospinal Fluid Samples in Alzheimer's Disease Research. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1367-1377.	1.2	0
89	BDNF-Met polymorphism and amyloid-beta in relation to cognitive decline in cognitively normal elderly: the SCIENCE project. <i>Neurobiology of Aging</i> , 2021, 108, 146-154.	1.5	6
90	Neurogranin as biomarker in CSF is non-specific to Alzheimer's disease dementia. <i>Neurobiology of Aging</i> , 2021, 108, 99-109.	1.5	13

#	ARTICLE	IF	CITATIONS
91	Comparing CSF amyloid β biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12182.	1.2	26
92	Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease. <i>Translational Psychiatry</i> , 2021, 11, 27.	2.4	207
93	Pathologically Decreased CSF Levels of Synaptic Marker NPTX2 in DLB Are Correlated with Levels of Alpha-Synuclein and VGF. <i>Cells</i> , 2021, 10, 38.	1.8	16
94	The global Alzheimer's Association round robin study on plasma amyloid β^2 methods. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12242.	1.2	17
95	Sex Hormone-Binding Globulin (SHBG) in Cerebrospinal Fluid Does Not Discriminate between the Main FTD Pathological Subtypes but Correlates with Cognitive Decline in FTD Tauopathies. <i>Biomolecules</i> , 2021, 11, 1484.	1.8	3
96	Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials. <i>Neurotherapeutics</i> , 2021, 18, 2351-2367.	2.1	12
97	Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. <i>Biomedicines</i> , 2021, 9, 1610.	1.4	7
98	Pre-analytical sample handling effects on blood cytokine levels: quality control of a COVID-19 biobank. <i>Biomarkers in Medicine</i> , 2021, 15, 987-997.	0.6	1
99	Gut Microbiota Composition Is Related to AD Pathology. <i>Frontiers in Immunology</i> , 2021, 12, 794519.	2.2	57
100	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. <i>Frontiers in Neurology</i> , 2021, 12, 805135.	1.1	12
101	Targeting MicroRNA-485-3p Blocks Alzheimer's Disease Progression. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13136.	1.8	20
102	Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	6
103	Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 198.	3.0	87
104	Clinical and analytical comparison of three assays for plasma p-tau isoforms on an ultrasensitive platform. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
105	Measuring synaptic loss in early AD stages: Trajectories of SNAP25 and SYT1 using serial CSF sampling. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
106	ATN classification in dementia with Lewy bodies: Association with clinical profile, cognitive decline and survival. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
107	Mapping associations across multiple aspects of Alzheimer disease and the role of CSF biomarkers in individuals without dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
108	Is A+T β Alzheimer's disease or not? A combined CSF and pathology study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0

#	ARTICLE	IF	CITATIONS
109	A panel of novel astrocytic and synaptic biomarkers in serum and CSF for the differential diagnosis of frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
110	Pre-analytical and clinical validation on the highway to implementation of novel dementia blood tests. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
111	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	7
112	Novel CSF inflammatory markers MIF and TREM-1 are increased in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
113	Apolipoprotein L1 is increased in frontotemporal lobar degeneration postmortem brain tissue but not in cerebrospinal fluid. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
114	Subjective cognitive decline and self-reported sleep at a memory clinic: The SCIENCE project. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
115	Cognitive decline in possible vascular cognitive impairment (VCI): Does the form of vascular brain injury matter?. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
116	Alzheimer's disease genetic risk variants show brain cell type-specific associations with protein levels in cerebrospinal fluid. <i>Alzheimer's and Dementia</i> , 2021, 17, e049531.	0.4	0
117	Associations between gut microbiota composition and AD biomarkers. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
118	Plasma p-tau181 levels predict amyloid pathology in cognitively unimpaired individuals after 10 years. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
119	Predicting institutionalization and mortality across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
120	Plasma NFL trajectory during ICU treatment of COVID-19 patients: A prospective cohort study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
121	CSF protein panels reflecting multiple pathophysiological mechanisms for early and specific diagnosis of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
122	The NeuroMET project: Metrology and innovation for early diagnosis and accurate stratification of patients with neurodegenerative diseases. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	5
123	Stability of the novel blood-based biomarkers under pre-analytical sample handling conditions: Results of the SABB-GBSC working group. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
124	Immune protein levels in cerebrospinal fluid: Associations with memory scores across the AD spectrum. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e055451.	0.4	0
125	Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 912-923.	1.4	52
126	Olfactory and gustatory functioning and food preferences of patients with Alzheimer's disease and mild cognitive impairment compared to controls: the NUDAD project. <i>Journal of Neurology</i> , 2020, 267, 144-152.	1.8	21

#	ARTICLE	IF	CITATIONS
127	Reply to "Usefulness of Plasma Amyloid as Prescreener of the Earliest Alzheimer Pathological Changes Depends on the Study Population". <i>Annals of Neurology</i> , 2020, 87, 155-155.	2.8	3
128	Cerebrospinal fluid proteomics and biological heterogeneity in Alzheimer's disease: A literature review. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2020, 57, 86-98.	2.7	40
129	Contactins & Alzheimer's Disease: Synaptic Proteins, Contactins may Contribute to the Pathology of Alzheimer's Disease. <i>Neuroscience</i> , 2020, 424, 182-183.	1.1	3
130	CSF or Serum Neurofilament Light Added to α -Synuclein Panel Discriminates Parkinson's From Controls. <i>Movement Disorders</i> , 2020, 35, 288-295.	2.2	69
131	Special Issue CCA for the proceedings of the 2nd symposium of the Society of CSF analysis and Clinical Neurochemistry. <i>Clinica Chimica Acta</i> , 2020, 502, 199-200.	0.5	0
132	Why Is Amyloid- β PET Requested After Performing CSF Biomarkers?. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 559-569.	1.2	8
133	Amyloid- β PET and CSF in an autopsy-confirmed cohort. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 2150-2160.	1.7	17
134	Energy intake and expenditure in patients with Alzheimer's disease and mild cognitive impairment: the NUDAD project. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 116.	3.0	18
135	Plasma NfL and GFAP as biomarkers of spinal cord degeneration in adrenoleukodystrophy. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 2127-2136.	1.7	19
136	Multitracer model for staging cortical amyloid deposition using PET imaging. <i>Neurology</i> , 2020, 95, e1538-e1553.	1.5	55
137	Serum neurofilament light as a biomarker in progressive multiple sclerosis. <i>Neurology</i> , 2020, 95, 436-444.	1.5	100
138	CSF Biomarkers Reflecting Protein Pathology and Axonal Degeneration Are Associated with Memory, Attentional, and Executive Functioning in Early-Stage Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8519.	1.8	7
139	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. <i>Translational Psychiatry</i> , 2020, 10, 403.	2.4	42
140	Plasma p-tau217: from "new kid" to most promising candidate for Alzheimer's disease blood test. <i>Brain</i> , 2020, 143, 3170-3172.	3.7	7
141	Comparison of ELISA- and SIMOA-based quantification of plasma $A\beta$ ratios for early detection of cerebral amyloidosis. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 162.	3.0	58
142	Personalized extended interval dosing of natalizumab in MS. <i>Neurology</i> , 2020, 95, e745-e754.	1.5	36
143	Neurofilament light chain as biomarker in idiopathic intracranial hypertension. <i>Cephalalgia</i> , 2020, 40, 1346-1354.	1.8	9
144	Blood platelet RNA enables the detection of multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020, 6, 205521732094678.	0.5	14

#	ARTICLE	IF	CITATIONS
145	Metabolic Age Based on the BBMRI-NL ¹ H-NMR Metabolomics Repository as Biomarker of Age-related Disease. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, 541-547.	1.6	50
146	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1353-1368.	1.2	7
147	Sex differences in CSF biomarkers vary by Alzheimer disease stage and APOE ϵ 4 genotype. <i>Neurology</i> , 2020, 95, e2378-e2388.	1.5	48
148	Contactin-1 Is Reduced in Cerebrospinal Fluid of Parkinson's Disease Patients and Is Present within Lewy Bodies. <i>Biomolecules</i> , 2020, 10, 1177.	1.8	14
149	Nutritional status and structural brain changes in Alzheimer's disease: The NUDAD project. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12063.	1.2	9
150	Identification of plasma proteome signatures associated with ATN framework using SOMAscan. <i>Alzheimer's and Dementia</i> , 2020, 16, e036954.	0.4	1
151	CSF proteomic changes in preclinical Alzheimer's disease: A monozygotic twin study. <i>Alzheimer's and Dementia</i> , 2020, 16, e038966.	0.4	0
152	Mild cognitive impairment with Lewy bodies: Clinical characteristics and risk factors for progression. <i>Alzheimer's and Dementia</i> , 2020, 16, e039094.	0.4	1
153	Relationship between clinical symptomatology and disease burden in dementia with Lewy bodies: An overview of the DEVELOP baseline results. <i>Alzheimer's and Dementia</i> , 2020, 16, e039306.	0.4	0
154	Single-cell profiling of circulating and brain-resident immune cells in a mouse model for amyloidosis and in aged mice. <i>Alzheimer's and Dementia</i> , 2020, 16, e041789.	0.4	0
155	Polygenic risk score for Alzheimer's disease is related to amyloid positivity in subjective cognitive decline: The SCIENCE project. <i>Alzheimer's and Dementia</i> , 2020, 16, e042116.	0.4	0
156	BDNF Met polymorphism on top of amyloid pathology predisposes for faster cognitive decline in cognitively normal elderly: The SCIENCE Project. <i>Alzheimer's and Dementia</i> , 2020, 16, e042728.	0.4	0
157	Development of an ultrasensitive multiplex assay for simultaneous detection of A β 1-42, A β 1-40, GFAP and NF κ L in blood. <i>Alzheimer's and Dementia</i> , 2020, 16, e043506.	0.4	2
158	Localization and protein levels of YKL40 in postmortem brain of frontotemporal dementia and Alzheimer's disease cases. <i>Alzheimer's and Dementia</i> , 2020, 16, e044523.	0.4	0
159	Serum glial fibrillary acidic protein and neurofilament light as prognostic biomarkers for clinical progression in subjective cognitive decline: The SCIENCE project. <i>Alzheimer's and Dementia</i> , 2020, 16, e044783.	0.4	1
160	Trajectories of decline in cognitively complex everyday activities across the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2020, 16, e044787.	0.4	1
161	Comparison of two analytical platforms for blood-based surrogate biomarkers of amyloid pathology. <i>Alzheimer's and Dementia</i> , 2020, 16, e045110.	0.4	0
162	Amyloid aggregation and subsequent memory decline over time in cognitively intact older identical twins. <i>Alzheimer's and Dementia</i> , 2020, 16, e045112.	0.4	0

#	ARTICLE	IF	CITATIONS
163	Using cerebrospinal fluid amyloid β (1 β 42) in the memory clinic: Concordance with PET and use of biomarker ratios across immunoassays. <i>Alzheimer's and Dementia</i> , 2020, 16, e045128.	0.4	3
164	Serum neurofilament light in memory clinic practice. <i>Alzheimer's and Dementia</i> , 2020, 16, e045155.	0.4	0
165	Amyloid pathology, but not vascular pathology, is associated with risk of incident dementia in non β -demented memory clinic participants. <i>Alzheimer's and Dementia</i> , 2020, 16, e045196.	0.4	0
166	Cerebrospinal fluid proteomic profiles predict progression to dementia in prodromal AD. <i>Alzheimer's and Dementia</i> , 2020, 16, e045230.	0.4	1
167	Plasma biomarkers predict amyloid pathology in cognitively unimpaired individuals. <i>Alzheimer's and Dementia</i> , 2020, 16, e045470.	0.4	0
168	Educational video increases patients' knowledge regarding the lumbar puncture procedure: Results of a randomized controlled trial in clinical practice. <i>Alzheimer's and Dementia</i> , 2020, 16, e045719.	0.4	0
169	Plasma amyloid β oligomerization assay as a screening test for abnormal amyloid status. <i>Alzheimer's and Dementia</i> , 2020, 16, e045754.	0.4	0
170	Comparative diagnostic performance of plasma P β tau217 and P β tau181 in Alzheimer's disease and frontotemporal lobar degeneration and correlations with [18F]Flortaucipir PET uptake. <i>Alzheimer's and Dementia</i> , 2020, 16, e045755.	0.4	0
171	A biorepository for the in β -depth validation of pre β -analytical sample handling effects on novel blood β -based biomarkers for Alzheimer's disease: The first results. <i>Alzheimer's and Dementia</i> , 2020, 16, e045763.	0.4	3
172	Identifying and predicting heterogeneity in cognitive decline among individuals with prodromal Alzheimer's disease using a latent class analysis. <i>Alzheimer's and Dementia</i> , 2020, 16, e045829.	0.4	1
173	CSF biomarkers for frontotemporal dementia and its pathological subtypes. <i>Alzheimer's and Dementia</i> , 2020, 16, e045851.	0.4	0
174	Prediction of amyloid PET status using the LUMIPULSE G β amyloid ratio (1 β 42/1 β 40). <i>Alzheimer's and Dementia</i> , 2020, 16, e046006.	0.4	1
175	Synaptic proteins relate to memory scores in preclinical Alzheimer's disease and cognitively healthy controls depending on amyloid. <i>Alzheimer's and Dementia</i> , 2020, 16, e046102.	0.4	0
176	International initiative for harmonization of cerebrospinal fluid diagnostic comments in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e047209.	0.4	1
177	CSF proteomic profiling of mild cognitive impairment individuals with suspected non β -Alzheimer's disease pathophysiology. <i>Alzheimer's and Dementia</i> , 2020, 16, e047247.	0.4	1
178	Working memory moderates the relation between the brain-derived neurotrophic factor (BDNF) and psychotherapy outcome for depression. <i>Journal of Psychiatric Research</i> , 2020, 130, 424-432.	1.5	17
179	Decline in cognitively complex everyday activities accelerates along the Alzheimer's disease continuum. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 138.	3.0	14
180	CDH6 and HAGH protein levels in plasma associate with Alzheimer's disease in APOE ϵ 4 carriers. <i>Scientific Reports</i> , 2020, 10, 8233.	1.6	17

#	ARTICLE	IF	CITATIONS
181	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 213-225.	1.2	13
182	Arylesterase Activity of Paraoxonase-1 in Serum and Cerebrospinal Fluid of Patients with Alzheimer's Disease and Vascular Dementia. <i>Antioxidants</i> , 2020, 9, 456.	2.2	17
183	APOE ϵ 4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 65.	3.0	28
184	ATN classification and clinical progression in subjective cognitive decline. <i>Neurology</i> , 2020, 95, e46-e58.	1.5	97
185	Maximizing Safety in the Conduct of Alzheimer's Disease Fluid Biomarker Research in the Era of COVID-19. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 27-31.	1.2	8
186	A multi-center study of neurofilament assay reliability and inter-laboratory variability. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 452-458.	1.1	15
187	High efavirenz levels but not neurofilament light plasma levels are associated with poor neurocognitive functioning in asymptomatic HIV patients. <i>Journal of NeuroVirology</i> , 2020, 26, 572-580.	1.0	6
188	Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach. <i>Molecular Neurodegeneration</i> , 2020, 15, 36.	4.4	46
189	Degree of genetic liability for Alzheimer's disease associated with specific proteomic profiles in cerebrospinal fluid. <i>Neurobiology of Aging</i> , 2020, 93, 144.e1-144.e15.	1.5	7
190	Gait Disturbances are Associated with Increased Cognitive Impairment and Cerebrospinal Fluid Tau Levels in a Memory Clinic Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 1061-1070.	1.2	13
191	Associations Between Nutrient Intake and Corresponding Nutritional Biomarker Levels in Blood in a Memory Clinic Cohort: The NUDAD Project. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 1436-1438.	1.2	1
192	Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. <i>Nature Medicine</i> , 2020, 26, 387-397.	15.2	471
193	Fingerprinting Alzheimer's Disease by ^1H Nuclear Magnetic Resonance Spectroscopy of Cerebrospinal Fluid. <i>Journal of Proteome Research</i> , 2020, 19, 1696-1705.	1.8	32
194	CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1585-1595.	1.2	25
195	Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project. <i>Neurobiology of Aging</i> , 2020, 89, 99-107.	1.5	34
196	Diurnal Cortisol Secretion Is Not Related to Multiple Sclerosis-Related Fatigue. <i>Frontiers in Neurology</i> , 2020, 10, 1363.	1.1	4
197	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy. <i>PLoS ONE</i> , 2020, 15, e0226784.	1.1	7
198	Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 612-621.	0.9	55

#	ARTICLE	IF	CITATIONS
199	Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2866-2878.	3.3	29
200	Sex-specific associations with cerebrospinal fluid biomarkers in dementia with Lewy bodies. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 44.	3.0	23
201	Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression. <i>Movement Disorders</i> , 2020, 35, 859-867.	2.2	33
202	Specific Nutritional Biomarker Profiles in Mild Cognitive Impairment and Subjective Cognitive Decline Are Associated With Clinical Progression: The NUDAD Project. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 1513.e1-1513.e17.	1.2	17
203	Understanding multifactorial brain changes in type 2 diabetes: a biomarker perspective. <i>Lancet Neurology</i> , The, 2020, 19, 699-710.	4.9	96
204	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. <i>Brain</i> , 2020, 143, 3776-3792.	3.7	89
205	Biomarker Testing: Piercing the Fog of Alzheimer's and Related Dementia. <i>Biomedicine Hub</i> , 2020, 5, 1-22.	0.4	7
206	Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 118.	3.0	129
207	Amyloid- β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 169.	3.0	31
208	Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias. <i>Neurology</i> , 2020, 95, e3026-e3035.	1.5	31
209	LDL cholesterol and uridine levels in blood are potential nutritional biomarkers of AD progression: The NUDAD project. <i>Alzheimer's and Dementia</i> , 2020, 16, .	0.4	2
210	LDL cholesterol and uridine levels in blood are potential nutritional biomarkers for clinical progression in Alzheimer's disease: The NUDAD project. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12120.	1.2	7
211	The appreciation of LED-based white light sources by Dutch and Chinese people in three application areas. <i>Lighting Research and Technology</i> , 2019, 51, 353-372.	1.2	12
212	Antibody-based methods for the measurement of β -synuclein concentration in human cerebrospinal fluid: method comparison and round robin study. <i>Journal of Neurochemistry</i> , 2019, 149, 126-138.	2.1	44
213	Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions. <i>Neurobiology of Aging</i> , 2019, 84, 225-234.	1.5	42
214	Plasma proteome in multiple sclerosis disease progression. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1582-1594.	1.7	21
215	Pre-analytical stability of novel cerebrospinal fluid biomarkers. <i>Clinica Chimica Acta</i> , 2019, 497, 204-211.	0.5	9
216	Retinal thickness as a potential biomarker in patients with amyloid-proven early and late-onset Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 463-471.	1.2	25

#	ARTICLE	IF	CITATIONS
217	Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. <i>Journal of Neurology</i> , 2019, 266, 2535-2545.	1.8	11
218	Applying the ATN scheme in a memory clinic population. <i>Neurology</i> , 2019, 93, e1635-e1646.	1.5	51
219	VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4674.	1.8	26
220	Amyloid- β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 83.	3.0	23
221	Cerebrospinal Fluid Amyloid- β Subtypes in Confirmed Frontotemporal Lobar Degeneration Cases: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 15-20.	1.2	2
222	Assessing the Pre-Analytical Stability of Small-Molecule Metabolites in Cerebrospinal Fluid Using Direct-Infusion Metabolomics. <i>Metabolites</i> , 2019, 9, 236.	1.3	9
223	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. <i>Lancet Neurology</i> , The, 2019, 18, 1103-1111.	4.9	128
224	Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 492-500.	1.8	5
225	Guidelines for CSF Processing and Biobanking: Impact on the Identification and Development of Optimal CSF Protein Biomarkers. <i>Methods in Molecular Biology</i> , 2019, 2044, 27-50.	0.4	19
226	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. <i>Alzheimer's and Dementia</i> , 2019, 15, 1478-1488.	0.4	46
227	Discordant amyloid- β PET and CSF biomarkers and its clinical consequences. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 78.	3.0	40
228	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. <i>Lancet Neurology</i> , The, 2019, 18, 1034-1044.	4.9	85
229	Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 8.	3.0	23
230	Associations of AD Biomarkers and Cognitive Performance with Nutritional Status: The NUDAD Project. <i>Nutrients</i> , 2019, 11, 1161.	1.7	25
231	Elecsys [®] Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. <i>Clinical Biochemistry</i> , 2019, 72, 30-38.	0.8	60
232	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. <i>JAMA Neurology</i> , 2019, 76, 1035.	4.5	455
233	Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 997-1004.	0.9	19
234	Systemic and intrathecal immune activation in association with cerebral and cognitive outcomes in paediatric HIV. <i>Scientific Reports</i> , 2019, 9, 8004.	1.6	17

#	ARTICLE	IF	CITATIONS
235	Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy. <i>Annals of Neurology</i> , 2019, 86, 322-324.	2.8	11
236	A β 234 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression. <i>Nature Communications</i> , 2019, 10, 2240.	5.8	39
237	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. <i>Alzheimer's and Dementia</i> , 2019, 15, 817-827.	0.4	62
238	Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal. <i>Neurology</i> , 2019, 92, e2699-e2705.	1.5	10
239	Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease?. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 383-391.	1.2	53
240	Inflammatory biomarkers in Alzheimer's disease plasma. <i>Alzheimer's and Dementia</i> , 2019, 15, 776-787.	0.4	134
241	Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 33.	3.0	30
242	ApoE and clusterin CSF levels influence associations between APOE genotype and changes in CSF tau, but not CSF A β 42, levels in non-demented elderly. <i>Neurobiology of Aging</i> , 2019, 79, 101-109.	1.5	12
243	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. <i>Alzheimer's and Dementia</i> , 2019, 15, 644-654.	0.4	90
244	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. <i>Alzheimer's and Dementia</i> , 2019, 15, 742-753.	0.4	82
245	Association of amyloid pathology with memory performance and cognitive complaints in cognitively normal older adults: a monozygotic twin study. <i>Neurobiology of Aging</i> , 2019, 77, 58-65.	1.5	14
246	The plasma peptides of breast versus ovarian cancer. <i>Clinical Proteomics</i> , 2019, 16, 43.	1.1	16
247	A metabolite-based machine learning approach to diagnose Alzheimer's type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 933-938.	1.8	70
248	Critical Steps to be Taken into Consideration Before Quantification of β -Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment. <i>Neurology and Therapy</i> , 2019, 8, 129-145.	1.4	8
249	PET and CSF amyloid- β 2 status are differently predicted by patient features: information from discordant cases. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 100.	3.0	21
250	gMS-Classifer1 does not predict disability progression in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1010-1011.	1.4	0
251	Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. <i>Alzheimer's and Dementia</i> , 2019, 15, 292-312.	0.4	310
252	Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 1-9.	1.2	14

#	ARTICLE	IF	CITATIONS
253	Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's diseaseâ€”Data from three memory clinic studies. <i>Alzheimer's and Dementia</i> , 2019, 15, 185-193.	0.4	28
254	Serum Neurofilament light correlates with CADASIL disease severity and survival. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 46-56.	1.7	24
255	Contactins in the central nervous system: role in health and disease. <i>Neural Regeneration Research</i> , 2019, 14, 206.	1.6	45
256	Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. <i>Neurology</i> , 2018, 90, e1231-e1239.	1.5	94
257	Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. <i>Clinical Chemistry</i> , 2018, 64, 927-937.	1.5	37
258	CNS penetration of ART in HIV-infected children. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 484-489.	1.3	21
259	Tracking disease progression noninvasively in Duchenne and Becker muscular dystrophies. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 715-726.	2.9	47
260	Poly(GP), neurofilament and grey matter deficits in <i>C9orf72</i> expansion carriers. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 583-597.	1.7	48
261	Plasma Amyloid- β^2 (A β^2) Correlates with Cerebrospinal Fluid A β^2 in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1857-1863.	1.2	100
262	A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline. <i>Human Brain Mapping</i> , 2018, 39, 3143-3151.	1.9	40
263	Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies. <i>Alzheimer's and Dementia</i> , 2018, 14, 707-722.	0.4	143
264	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 30.	3.0	40
265	Disease-related determinants are associated with mortality in dementia due to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 23.	3.0	20
266	Prevalence of the apolipoprotein E ϵ^4 allele in amyloid β^2 positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.	0.4	58
267	Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment. <i>Multiple Sclerosis Journal</i> , 2018, 24, 472-480.	1.4	30
268	Brain endothelial cell expression of SPARCL1 is specific to chronic multiple sclerosis lesions and is regulated by inflammatory mediators <i>in vitro</i> . <i>Neuropathology and Applied Neurobiology</i> , 2018, 44, 404-416.	1.8	9
269	Upward drift in cerebrospinal fluid amyloid β^2 42 assay values for more than 10 years. <i>Alzheimer's and Dementia</i> , 2018, 14, 62-70.	0.4	50
270	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 244-328.	1.3	215

#	ARTICLE	IF	CITATIONS
271	Gray matter networks and clinical progression in subjects with predementia Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 61, 75-81.	1.5	52
272	Gray matter network measures are associated with cognitive decline in mild cognitive impairment. <i>Neurobiology of Aging</i> , 2018, 61, 198-206.	1.5	44
273	Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	6.0	133
274	Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid- β 1 β 42 Analysis Results. <i>Clinical Chemistry</i> , 2018, 64, 576-585.	1.5	126
275	O1 β 10 β 06: CONTACTIN β 1 HAS ADDED VALUE FOR DISCRIMINATION OF DEMENTIA WITH LEWY BODIES FROM ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P245.	0.4	0
276	F2 β 02 β 04: NEUROFILAMENTS TO MEASURE TREATMENT EFFICACY IN MS. <i>Alzheimer's and Dementia</i> , 2018, 14, P604.	0.4	0
277	P2 β 248: CONTACTIN β 2 AS A POTENTIAL BIOMARKER FOR MILD COGNITIVE IMPAIRMENT. <i>Alzheimer's and Dementia</i> , 2018, 14, P768.	0.4	0
278	P2 β 228: PRE β ANALYTICAL STABILITY OF NOVEL CEREBROSPINAL FLUID BIOMARKERS FOR DEMENTIA. <i>Alzheimer's and Dementia</i> , 2018, 14, P755.	0.4	0
279	O2 β 04 β 02: LONGITUDINAL COGNITIVE TRAJECTORIES OF PATIENTS WITH DISCORDANT CSF AND PET AMYLOID BIOMARKERS. <i>Alzheimer's and Dementia</i> , 2018, 14, P621.	0.4	0
280	P1 β 525: AMYLOID AGGREGATION IS ASSOCIATED WITH DECLINE ON DIGIT SPAN BACKWARD IN COGNITIVELY NORMAL ELDERLY MONOZYGOTIC TWINS. <i>Alzheimer's and Dementia</i> , 2018, 14, P533.	0.4	0
281	P1 β 297: METABOLIC BLOOD β BASED BIOMARKERS RELATE TO BRAIN ATROPHY AND WHITE MATTER HYPERINTENSITIES IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P401.	0.4	0
282	P3 β 289: HARMONIZATION OF SCD OPERATIONALIZATION ACROSS DIFFERENT MEMORY CLINIC SETTINGS: THE EURO β SCD STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P1191.	0.4	0
283	O2 β 09 β 03: DIAGNOSTIC PERFORMANCE OF ELECSYS IMMUNOASSAYS FOR CEREBROSPINAL FLUID ALZHEIMER'S DISEASE BIOMARKERS IN A NON β ACADEMIC MULTICENTER MEMORY CLINIC COHORT: THE ABIDE PROJECT. <i>Alzheimer's and Dementia</i> , 2018, 14, P641.	0.4	0
284	P3 β 264: UNBIASED METHOD TO DETERMINE CUT β POINTS FOR CSF TOTAL TAU LEVELS REVEALS PRESENCE OF BIOLOGICAL SUBTYPES IN A LARGE ALZHEIMER'S DISEASE POPULATION. <i>Alzheimer's and Dementia</i> , 2018, 14, P1176.	0.4	0
285	DT β 02 β 02: NOVEL ULTRASENSITIVE IMMUNOASSAY DETECTING P β TAU THR217 COMPLETELY DISTINGUISHES ALZHEIMER'S DISEASE FROM FRONTOTEMPORAL LOBAR DEGENERATION. <i>Alzheimer's and Dementia</i> , 2018, 14, P1669.	0.4	0
286	O2 β 14 β 04: IDENTIFYING BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA AMONG PATIENTS WITH A LATE β ONSET FRONTAL LOBE SYNDROME: SUMMARY RESULTS OF THE LOF STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P657.	0.4	0
287	No Plasmatic Proteomic Signature at Clinical Disease Onset Associated With 11 Year Clinical, Cognitive and MRI Outcomes in Relapsing-Remitting Multiple Sclerosis Patients. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 371.	1.4	3
288	O2 β 15 β 06: CSF AMYLOID β 2 PEPTIDES IN DEMENTIA WITH LEWY BODIES AND ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P663.	0.4	0

#	ARTICLE	IF	CITATIONS
289	O3â€14â€03: IDENTIFICATION OF NOVEL CEREBROSPINAL FLUID BIOMARKER CANDIDATES FOR DEMENTIA WITH LEWY BODIES: A PROTEOMIC APPROACH. <i>Alzheimer's and Dementia</i> , 2018, 14, P1060.	0.4	0
290	O2â€15â€04: ROBUST INDIVIDUALIZED PREDICTION MODELS WHICH ARE APPLICABLE ACROSS DIFFERENT COHORTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P661.	0.4	0
291	O5â€01â€03: ATROPHY SUBTYPES IN ALZHEIMER'S DISEASE IDENTIFIED THROUGH NONâ€NEGATIVE MATRIX FACTORIZATION. <i>Alzheimer's and Dementia</i> , 2018, 14, P1638.	0.4	0
292	P2â€284: NUTRITIONAL MARKERS ASSOCIATED WITH CLINICAL PROGRESSION IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND SUBJECTIVE COGNITIVE DECLINE: THE NUDAD STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P789.	0.4	0
293	F4â€08â€01: PLASMA AMYLOID AS A PREâ€SCREENING TOOL FOR AMYLOID POSITIVITY IN SUBJECTIVE COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1394.	0.4	0
294	O2â€09â€04: HARMONIZATION OF IMMUNOCHEMICAL METHODS FOR MEASUREMENT OF Î±â€SYNUCLEIN IN HUMAN CEREBROSPINAL FLUID: A ROUND ROBIN STUDY APPROACH. <i>Alzheimer's and Dementia</i> , 2018, 14, P642.	0.4	0
295	Î±â€Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies. <i>Movement Disorders</i> , 2018, 33, 1724-1733.	2.2	79
296	Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study. <i>BMC Geriatrics</i> , 2018, 18, 289.	1.1	25
297	Differential Expression of Tissue Transglutaminase Splice Variants in Peripheral Blood Mononuclear Cells of Primary Progressive Multiple Sclerosis Patients. <i>Medical Sciences (Basel, Switzerland)</i> , 2018, 6, 108.	1.3	3
298	Computerâ€assisted prediction of clinical progression in the earliest stages of AD. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 726-736.	1.2	8
299	Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731881953.	0.5	19
300	Angiopoietin like-4 as a novel vascular mediator in capillary cerebral amyloid angiopathy. <i>Brain</i> , 2018, 141, 3377-3388.	3.7	32
301	P1â€247: CEREBROSPINAL FLUID NEUROFILAMENT LIGHT PROTEIN AS A DIFFERENTIAL DIAGNOSIS BIOMARKER IN NEUROLOGICAL DISEASES: A SYSTEMATIC REVIEW AND METAANALYSIS. <i>Alzheimer's and Dementia</i> , 2018, 14, P373.	0.4	1
302	The plasma peptides of ovarian cancer. <i>Clinical Proteomics</i> , 2018, 15, 41.	1.1	33
303	The plasma peptidome. <i>Clinical Proteomics</i> , 2018, 15, 39.	1.1	22
304	Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 409.	1.7	28
305	Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 563-572.	1.2	52
306	The Bri2 and Bri3 BRICHOS Domains Interact Differently with AÎ²42 and Alzheimer Amyloid Plaques. <i>Journal of Alzheimer's Disease Reports</i> , 2018, 2, 27-39.	1.2	27

#	ARTICLE	IF	CITATIONS
307	O3â€9â€06: A PROTOTYPE SIMOA ASSAY QUANTIFYING PLASMA AMYLOID BETA 1â€42 AND 1â€40 ISOFORMS CAN DIFFERENTIATE PARTICIPANTS WITH AD FROM HEALTHY CONTROL SUBJECTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1039.	0.4	4
308	Atrophy subtypes in prodromal Alzheimerâ€™s disease are associated with cognitive decline. <i>Brain</i> , 2018, 141, 3443-3456.	3.7	102
309	Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimerâ€™s disease: results of a randomized, double-blind, placebo-controlled phase 2a study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 107.	3.0	80
310	Clinical phenotype, atrophy, and small vessel disease in ϵ -APOE ϵ 2 carriers with Alzheimer disease. <i>Neurology</i> , 2018, 91, e1851-e1859.	1.5	46
311	Interlaboratory proficiency processing scheme in CSF aliquoting: implementation and assessment based on biomarkers of Alzheimerâ€™s disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 87.	3.0	13
312	Novel τ -CSF biomarkers to discriminate τ -FTLD and its pathological subtypes. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1163-1175.	1.7	20
313	Plasma Amyloid as Prescreener for the Earliest τ -Alzheimer Pathological Changes. <i>Annals of Neurology</i> , 2018, 84, 648-658.	2.8	230
314	The EMIF-AD PreclinAD study: study design and baseline cohort overview. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 75.	3.0	48
315	Neurofilaments as biomarkers in neurological disorders. <i>Nature Reviews Neurology</i> , 2018, 14, 577-589.	4.9	1,177
316	Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment. <i>Neuro-Oncology</i> , 2018, 20, 1494-1504.	0.6	50
317	Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2018, 19, 625-632.	1.4	23
318	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. <i>Alzheimer's and Dementia</i> , 2018, 14, 1313-1333.	0.4	87
319	Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimerâ€™s disease and vascular dementia. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 58.	3.0	21
320	Preâ€amyloid stage of Alzheimer's disease in cognitively normal individuals. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1037-1047.	1.7	23
321	Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimerâ€™s disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 52.	3.0	18
322	Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 111.	1.7	29
323	Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimerâ€™s disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 5.	3.0	94
324	Disease trajectories in behavioural variant frontotemporal dementia, primary psychiatric and other neurodegenerative disorders presenting with behavioural change. <i>Journal of Psychiatric Research</i> , 2018, 104, 183-191.	1.5	21

#	ARTICLE	IF	CITATIONS
325	Subjective Cognitive Impairment Cohort (SCIENCE): study design and first results. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 76.	3.0	87
326	The use of cerebrospinal fluid in biomarker studies. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 146, 3-20.	1.0	21
327	Characterising user preference for white LED light sources with CIE colour rendering index combined with a relative gamut area index. <i>Lighting Research and Technology</i> , 2017, 49, 461-480.	1.2	25
328	Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 687-697.	1.2	60
329	Comparison of multiplex platforms for cytokine assessments and their potential use for biomarker profiling in multiple sclerosis. <i>Cytokine</i> , 2017, 91, 145-152.	1.4	17
330	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 543-555.	1.2	10
331	Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 143-151.	1.2	57
332	How to handle adsorption of cerebrospinal fluid amyloid $A\beta_{1-42}$ in laboratory practice? Identifying problematic handlings and resolving the issue by use of the $A\beta_{42}/A\beta_{40}$ ratio. , 2017, 13, 885-892.		52
333	Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. <i>Alzheimer's and Dementia</i> , 2017, 13, 903-912.	0.4	32
334	A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/ $A\beta_{42}$ cutoff with concordance to amyloid positron emission tomography imaging. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 201-209.	1.2	19
335	Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 113-118.	0.9	100
336	Unbiased estimates of cerebrospinal fluid $A\beta_{1-42}$ cutoffs in a large memory clinic population. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 8.	3.0	60
337	Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts. <i>Alzheimer's and Dementia</i> , 2017, 13, 1226-1236.	0.4	59
338	CSF ApoE predicts clinical progression in nondemented $APOE\epsilon_4$ carriers. <i>Neurobiology of Aging</i> , 2017, 57, 186-194.	1.5	26
339	Effect of long-term storage in biobanks on cerebrospinal fluid biomarker $A\beta_{1-42}$, Tau, and P-tau values. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 45-50.	1.2	21
340	Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 139-146.	1.2	19
341	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 111-126.	1.2	197
342	Glutaminyl cyclase activity correlates with levels of $A\beta$ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer's disease patients. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 38.	3.0	24

#	ARTICLE	IF	CITATIONS
343	Selective impairment of hippocampus and posterior hub areas in Alzheimer's disease: an MEG-based multiplex network study. <i>Brain</i> , 2017, 140, 1466-1485.	3.7	132
344	Design of the ExCersion-VCI study: The effect of aerobic exercise on cerebral perfusion in patients with vascular cognitive impairment. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 157-165.	1.8	15
345	Cerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatric disorders. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 7, 99-106.	1.2	32
346	Low normal cerebrospinal fluid A β 242 levels predict clinical progression in nondemented subjects. <i>Annals of Neurology</i> , 2017, 81, 749-753.	2.8	20
347	Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1025-1034.	1.2	33
348	Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project. <i>JAMA Neurology</i> , 2017, 74, 1481.	4.5	77
349	Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1119-1128.	1.2	27
350	A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 13333.	1.6	45
351	Blood-based metabolic signatures in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 196-207.	1.2	56
352	Lumbar puncture in patients with neurologic conditions. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 108-110.	1.2	12
353	[P4-146]: NEUROFILAMENT LIGHT CHAIN AND PHOSPHOTAU/TAU RATIO AS CSF BIOMARKERS IN FRONTOTEMPORAL DEMENTIA. <i>Alzheimer's and Dementia</i> , 2017, 13, P1313.	0.4	0
354	[P4-151]: ALPHA-SYNUCLEIN BIOMARKER ANALYSIS: ANALYTICAL PERFORMANCE AND INTER-LABORATORY PRECISION USING A NEW COLORIMETRIC ELISA. <i>Alzheimer's and Dementia</i> , 2017, 13, P1316.	0.4	0
355	[P2-245]: AMYLOID VISUALIZATION IN THE RETINA OF ALZHEIMER'S DISEASE PATIENTS WITH CURCUMIN. <i>Alzheimer's and Dementia</i> , 2017, 13, P705.	0.4	0
356	Gray matter network differences between behavioral variant frontotemporal dementia and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 50, 77-86.	1.5	6
357	[P1-243]: ALPHA-SYNUCLEIN SPECIES AS POTENTIAL CSF BIOMARKERS FOR DEMENTIA WITH LEWY BODIES. <i>Alzheimer's and Dementia</i> , 2017, 13, P338.	0.4	2
358	[P3-161]: GRANULOCYTES: KEY PLAYERS IN PERIPHERAL A β CLEARANCE?. <i>Alzheimer's and Dementia</i> , 2017, 13, P995.	0.4	0
359	[P3-226]: PROFILING PERIPHERAL METABOLIC DYSREGULATION IN ALZHEIMER'S DISEASE: THE ADDED VALUE OF MULTIPLE SIGNATURES. <i>Alzheimer's and Dementia</i> , 2017, 13, P1024.	0.4	0
360	[ICP-005]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOID β AND [¹⁸ F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS. <i>Alzheimer's and Dementia</i> , 2017, 13, P13.	0.4	1

#	ARTICLE	IF	CITATIONS
361	[Icâ€“055]: EFFECT OF APOEâ€“2 ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P45.	0.4	0
362	[Icâ€“058]: TWIN CORRELATIONS FOR AMYLOID PATHOLOGY MEASURED WITH POSITRON EMISSION TOMOGRAPHY AND IN CEREBROSPINAL FLUID IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P47.	0.4	0
363	[P1â€“250]: DECISION TREE ANALYSIS REVEALS TWO CUTâ€“OFF LEVELS FOR AMYLOID BETA IN EARLY AD DIAGNOSIS. Alzheimer's and Dementia, 2017, 13, P342.	0.4	0
364	[P1â€“276]: BRI2 DEMENTIA PATHWAY IN CSF, IMPROVING DETECTION THROUGH ULTRASENSITIVE SIMOA TECHNOLOGY. Alzheimer's and Dementia, 2017, 13, P355.	0.4	0
365	[P2â€“203]: SPPL2B: A NOVEL PROTEIN RELATED TO TAU PATHOLOGY IN ALZHEIMER'S DISEASE?. Alzheimer's and Dementia, 2017, 13, P684.	0.4	0
366	[P2â€“207]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOIDâ€“2 AND [¹⁸ F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS. Alzheimer's and Dementia, 2017, 13, P688.	0.4	0
367	[P2â€“242]: PROTEOMICS IDENTIFICATION OF NOVEL CEREBROSPINAL FLUID BIOMARKER CANDIDATES OF DEMENTIA WITH LEWY BODIES. Alzheimer's and Dementia, 2017, 13, P704.	0.4	0
368	[P2â€“249]: CONTACTINâ€“1 IN CSF DISCRIMINATES DEMENTIA WITH LEWY BODIES (DLB) FROM AD AND NONâ€“DEMENTED CONTROLS. Alzheimer's and Dementia, 2017, 13, P708.	0.4	0
369	[P2â€“335]: EFFECT OF APOEâ€“2 ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P748.	0.4	0
370	[P2â€“338]: ARE NEUROFILAMENT LIGHT CHAIN AND WHITE MATTER INTEGRITY RELATED BIOMARKERS FOR FAMILIAL FRONTOTEMPORAL DEMENTIA?. Alzheimer's and Dementia, 2017, 13, P751.	0.4	1
371	[F1â€“03â€“04]: BIOMARKERâ€“BASED PERSONALIZED RISK ESTIMATES FOR PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P177.	0.4	0
372	[O1â€“05â€“03]: CSF AMYLOID BETA 1â€“42 LEVELS OBTAINED OVER 15 YEARS SHOW A DIAGNOSISâ€“DEPENDENT UPWARD DRIFT. Alzheimer's and Dementia, 2017, 13, P198.	0.4	0
373	[O1â€“05â€“04]: CLINICAL PERFORMANCE OF NEUROGRANIN AS A CEREBROSPINAL FLUID BIOMARKER FOR ALZHEIMER'S DISEASE: AN ASSAY COMPARISON STUDY. Alzheimer's and Dementia, 2017, 13, P199.	0.4	0
374	[O2â€“01â€“01]: CHARACTERIZING INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE: THE SUBJECTIVE COGNITIVE IMPAIRMENT COHORT (SCIENCE). Alzheimer's and Dementia, 2017, 13, P547.	0.4	0
375	[O2â€“05â€“01]: TWIN CORRELATIONS FOR AMYLOID PATHOLOGY MEASURED WITH POSITRON EMISSION TOMOGRAPHY AND IN CEREBROSPINAL FLUID IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P559.	0.4	0
376	[O2â€“10â€“06]: PROGNOSIS OF CLINICAL PROGRESSION IN SUBJECTIVE COGNITIVE DECLINE USING A CLINICAL DECISION SUPPORT SYSTEM. Alzheimer's and Dementia, 2017, 13, P579.	0.4	0
377	[O3â€“10â€“03]: LONGITUDINAL CEREBROSPINAL FLUID BIOMARKER TRAJECTORIES ALONG THE ALZHEIMER'S DISEASE CONTINUUM: A MULTICENTRE EUROPEAN STUDY. Alzheimer's and Dementia, 2017, 13, P924.	0.4	3
378	Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 61, 309-320.	1.2	27

#	ARTICLE	IF	CITATIONS
379	[P2â€“194]: USING EMERGING CEREBROSPINAL FLUID MARKERS TO CHARACTERIZE SUSPECTED NONâ€“ALZHEIMER'S DISEASE PATHOPHYSIOLOGY (SNAP) IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT. <i>Alzheimer's and Dementia</i> , 2017, 13, P680.	0.4	0
380	[P3â€“075]: PLEIOTROPHIN, A NEW BIOMARKER FOR AD, IDENTIFIED USING A NOVEL STRATEGY IN CLINICAL PROTEOMICS. <i>Alzheimer's and Dementia</i> , 2017, 13, P960.	0.4	0
381	Multicenter Analytical Validation of AÎ²40 Immunoassays. <i>Frontiers in Neurology</i> , 2017, 8, 310.	1.1	10
382	Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 201-210.	1.2	11
383	Regulator of oligodendrocyte maturation, miR-219, a potential biomarker for MS. <i>Journal of Neuroinflammation</i> , 2017, 14, 235.	3.1	41
384	Monocyte-derived tissue transglutaminase in multiple sclerosis patients: reflecting an anti-inflammatory status and function of the cells?. <i>Journal of Neuroinflammation</i> , 2017, 14, 257.	3.1	15
385	Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 73.	3.0	25
386	Inflammatory and Neuronal Biomarkers Associated With Retinal Thinning in Pediatric HIV. , 2017, 58, 5985.		4
387	Detection of contactin-2 in cerebrospinal fluid (CSF) of patients with Alzheimer's disease using Fluorescence Correlation Spectroscopy (FCS). <i>Clinical Biochemistry</i> , 2017, 50, 1061-1066.	0.8	16
388	Fluid biomarkers for disease activity in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1660-1661.	1.4	4
389	Integrating Biomarkers for Underlying Alzheimerâ€™s Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 261-270.	1.2	14
390	Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, jnnp-2014-309690.	0.9	90
391	Stability of Progranulin Under Pre-Analytical Conditions in Serum and Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 107-116.	1.2	5
392	Neurometabolite Alterations Associated With Cognitive Performance in Perinatally HIV-Infected Children. <i>Medicine (United States)</i> , 2016, 95, e3093.	0.4	22
393	Non-Phosphorylated Tau as a Potential Biomarker of Alzheimerâ€™s Disease: Analytical and Diagnostic Characterization. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 159-170.	1.2	23
394	Heterogeneous Language Profiles in Patients with Primary Progressive Aphasia due to Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 581-590.	1.2	35
395	IC-03-02: Grey Matter Connectivity is Associated with Clinical Progression in Non-Demented, Amyloid Positive Patients. , 2016, 12, P9-P10.		0
396	O3â€“08â€“01: Grey Matter Connectivity is Associated with Time to Clinical Progression in Mild Cognitive Impairment, Independent of Amyloid Status. <i>Alzheimer's and Dementia</i> , 2016, 12, P303.	0.4	0

#	ARTICLE	IF	CITATIONS
397	P103: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Non-Demented Stages of Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P78.	0.4	0
398	P144: Cognitive Subtypes Identified Using Nonnegative Matrix Factorisation in Four Large Alzheimer's Disease Dementia Cohorts. Alzheimer's and Dementia, 2016, 12, P873.	0.4	0
399	P112: Amyloid Levels in the Normal Range are Predictive for Incident Dementia in Non-Demented Elderly. Alzheimer's and Dementia, 2016, 12, P1055.	0.4	0
400	P224: Alzheimer's Disease Patients With Osas History Have Higher CSF Tau Levels. Alzheimer's and Dementia, 2016, 12, P1115.	0.4	3
401	O1-01-01: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Non-Demented Stages of Alzheimer's Disease. , 2016, 12, P169-P170.		0
402	O10502: Effects of Up to 14 Years of Biobank Storage of CSF Biomarkers AB42, TTAU, and PTAU. Alzheimer's and Dementia, 2016, 12, P183.	0.4	0
403	O4-09-04: Towards Data-Driven Medicine in Differential Diagnostics of Neurodegenerative Diseases. , 2016, 12, P355-P355.		0
404	O50503: Novel CSF Biomarkers Discriminating FTLD-TDP from Non-Demented Controls. Alzheimer's and Dementia, 2016, 12, P388.	0.4	0
405	P1174: Cost-Efficient Differential Diagnostics of Neurodegenerative Diseases Using A Stratified Approach. Alzheimer's and Dementia, 2016, 12, P469.	0.4	0
406	Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study. Journal of Alzheimer's Disease, 2016, 55, 585-595.	1.2	41
407	New <sc>CSF</sc> biomarkers on the block. EMBO Molecular Medicine, 2016, 8, 1118-1119.	3.3	4
408	The inflammatory marker GDF-15 is not independently associated with late-life depression. Journal of Psychosomatic Research, 2016, 83, 46-49.	1.2	9
409	Design of the N-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 233-240.	1.8	4
410	Multicenter immunoassay validation of cerebrospinal fluid neurofilament light: a biomarker for neurodegeneration. Bioanalysis, 2016, 8, 2243-2254.	0.6	14
411	Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort. Journal of Alzheimer's Disease, 2016, 54, 287-295.	1.2	77
412	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. Journal of Alzheimer's Disease, 2016, 52, 51-64.	1.2	18
413	Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2016, 3, 623-636.	1.7	207
414	S4-01-01: Cross-Sectional Studies of Plasma Proteomic Biomarkers Relating to Pet Amyloid and CSF Amyloid and Tau. , 2016, 12, P321-P321.		0

#	ARTICLE	IF	CITATIONS
415	P2-166: Retinal Thickness in Alzheimer's Disease: A Potential Diagnostic Biomarker? Evidence from an Amyloid Proven Early Onset Alzheimer's Disease Cohort. <i>Alzheimer's and Dementia</i> , 2016, 12, P678.	0.4	1
416	P2-335: Prevalence of Preclinical Alzheimer's Disease in Patients with Subjective Cognitive Decline: Comparison of Three European Memory Clinic Samples. <i>Alzheimer's and Dementia</i> , 2016, 12, P770.	0.4	0
417	O5-07-02: Personalized Risk Estimates for MCI Patients: Taking Biomarkers Into the Clinic. , 2016, 12, P393-P393.		1
418	Validation of soluble amyloid β precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases. <i>Journal of Neurochemistry</i> , 2016, 137, 112-121.	2.1	17
419	Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2016, 11, 7.	4.4	198
420	Cerebral perfusion in the prodementia stages of Alzheimer's disease. <i>European Radiology</i> , 2016, 26, 506-514.	2.3	99
421	Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 2, 86-94.	1.2	68
422	Cholesterol and markers of cholesterol turnover in multiple sclerosis: relationship with disease outcomes. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 5, 53-65.	0.9	77
423	Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of amyloid (1-42) in human cerebrospinal fluid. <i>Alzheimer's and Dementia</i> , 2016, 12, 517-526.	0.4	254
424	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. <i>Alzheimer's and Dementia</i> , 2016, 12, 154-163.	0.4	179
425	Use of amyloid-PET to determine cutpoints for CSF markers. <i>Neurology</i> , 2016, 86, 50-58.	1.5	54
426	The identification of cognitive subtypes in Alzheimer's disease dementia using latent class analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 235-243.	0.9	89
427	P3-072: Are relations between ApoE genotype and AD-related pathology in nondemented elderly mediated by CSF apolipoproteins?. , 2015, 11, P644-P644.		0
428	Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 505-512.	1.2	81
429	O1-03-03: Olfactory dysfunction may predict Alzheimer's disease related tau pathology in cerebrospinal fluid (CSF). , 2015, 11, P130-P130.		0
430	O4-03-01: Early detection of Alzheimer's disease (AD)-related amyloid and tau pathology: A computerized versus a paper-and-pencil memory test. , 2015, 11, P272-P272.		0
431	P2-298: Altered plasma and CSF levels of nutrients that enhance neuronal phospholipid synthesis in Alzheimer's disease: A retrospective cohort study. , 2015, 11, P606-P607.		0
432	Amyloid β Oligomers Relate to Cognitive Decline in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 35-43.	1.2	52

#	ARTICLE	IF	CITATIONS
433	Matrix Metalloproteinases in Alzheimer's Disease and Concurrent Cerebral Microbleeds. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 711-720.	1.2	71
434	Serum Leptin is not Altered nor Related to Cognitive Decline in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 809-813.	1.2	42
435	P1-180: Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. , 2015, 11, P414-P414.		0
436	Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 889-899.	1.2	11
437	Can agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease?. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 75-80.	1.2	4
438	O4-11-04: Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lp feasibility study. , 2015, 11, P297-P297.		1
439	Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis. <i>Proteomics</i> , 2015, 15, 3361-3369.	1.3	32
440	Inhaled carbon monoxide protects time-dependently from loss of hypoxic pulmonary vasoconstriction in endotoxemic mice. <i>Respiratory Research</i> , 2015, 16, 119.	1.4	6
441	A Practical Guide to Immunoassay Method Validation. <i>Frontiers in Neurology</i> , 2015, 6, 179.	1.1	348
442	Facilitating the Validation of Novel Protein Biomarkers for Dementia: An Optimal Workflow for the Development of Sandwich Immunoassays. <i>Frontiers in Neurology</i> , 2015, 6, 202.	1.1	24
443	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , 2015, 6, 216.	1.1	36
444	Guidelines on Cerebrospinal Fluid Analysis. , 2015, , 407-428.		1
445	Importance of Pre-analytical Stability for CSF Biomarker Testing. , 2015, , 59-77.		6
446	Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics. <i>Alzheimer's and Dementia</i> , 2015, 11, 1191-1201.	0.4	71
447	P1-120: Standardization of a method for diagnostic biomarker validation for neurodegenerative diseases: App assays as example. , 2015, 11, P387-P387.		0
448	P4-242: A case-control cohort study to define a threshold for the tau/abeta42 ratio in cerebrospinal fluid optimized for diagnosis of Alzheimer's disease. , 2015, 11, P873-P873.		0
449	O4-11-01: Multicentre performance evaluation of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of A β (1-42) in human cerebrospinal fluid. , 2015, 11, P295-P296.		0
450	P3-142: Alzheimer's biomarkers in daily practice (ABIDE): Study design. , 2015, 11, P679-P680.		0

#	ARTICLE	IF	CITATIONS
451	O1-07-02: Alzheimer's disease core biomarkers and prediction of dementia in MCI: The effect of age at onset. , 2015, 11, P140-P142.		0
452	O3-14-02: Assessing underlying Alzheimer's disease pathology in MCI patients from the amsterdam dementia cohort by use of the predictad software tool. , 2015, 11, P254-P255.		0
453	O5-05-03: Neurogranin, a CSF biomarker for synaptic loss, predicts decline to dementia due to Alzheimer's disease. , 2015, 11, P326-P326.		0
454	The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease. Neurobiology of Aging, 2015, 36, 1605.e13-1605.e20.	1.5	27
455	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal, 2015, 21, 1013-1024.	1.4	249
456	Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinic. Alzheimer's and Dementia, 2015, 11, 523-532.	0.4	59
457	Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1180-1190.	0.4	254
458	Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy. Multiple Sclerosis Journal, 2015, 21, 481-484.	1.4	18
459	Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. Neurobiology of Aging, 2015, 36, 2340-2347.	1.5	49
460	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain, 2015, 138, 2701-2715.	3.7	109
461	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain, 2015, 138, 918-931.	3.7	147
462	Accumulation of BRI2-BRICHOS ectodomain correlates with a decreased clearance of A β by insulin degrading enzyme (IDE) in Alzheimer's disease. Neuroscience Letters, 2015, 589, 47-51.	1.0	13
463	Angiotensin-Converting Enzyme in Cerebrospinal Fluid and Risk of Brain Atrophy. Journal of Alzheimer's Disease, 2015, 44, 153-162.	1.2	18
464	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
465	Mild cognitive impairment with suspected nonamyloid pathology (SNAP). Neurology, 2015, 84, 508-515.	1.5	122
466	Standard biobanking conditions prevent evaporation of body fluid samples. Clinica Chimica Acta, 2015, 442, 141-145.	0.5	11
467	Body fluid biomarkers for multiple sclerosis—the long road to clinical application. Nature Reviews Neurology, 2015, 11, 585-596.	4.9	88
468	Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. Alzheimer's Research and Therapy, 2015, 7, 59.	3.0	101

#	ARTICLE	IF	CITATIONS
469	Biobanking of Cerebrospinal Fluid for Biomarker Analysis in Neurological Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2015, 864, 79-93.	0.8	12
470	Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. <i>JAMA Neurology</i> , 2015, 72, 1275.	4.5	183
471	Techniques, Contraindications, and Complications of CSF Collection Procedures. , 2015, , 35-57.		12
472	Variability of CSF Alzheimer's Disease Biomarkers: Implications for Clinical Practice. <i>PLoS ONE</i> , 2014, 9, e100784.	1.1	72
473	SUCLG2 identified as both a determinant of CSF A β 42 levels and an attenuator of cognitive decline in Alzheimer's disease. <i>Human Molecular Genetics</i> , 2014, 23, 6644-6658.	1.4	45
474	The Dutch Parelinoer Institute - Neurodegenerative diseases; methods, design and baseline results. <i>BMC Neurology</i> , 2014, 14, 254.	0.8	57
475	Role of BRI2 in Dementia. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 481-494.	1.2	21
476	N-Acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. <i>Journal of Neurology</i> , 2014, 261, 2338-2343.	1.8	52
477	Associations Between Cerebral Small-Vessel Disease and Alzheimer Disease Pathology as Measured by Cerebrospinal Fluid Biomarkers. <i>JAMA Neurology</i> , 2014, 71, 855.	4.5	140
478	Oxysterols and cholesterol precursors correlate to magnetic resonance imaging measures of neurodegeneration in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 412-417.	1.4	70
479	Building a New Paradigm for the Early Recognition of Behavioral Variant Frontotemporal Dementia: Late Onset Frontal Lobe Syndrome Study. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 735-740.	0.6	30
480	Proteomic analysis of cerebrospinal fluid extracellular vesicles: A comprehensive dataset. <i>Journal of Proteomics</i> , 2014, 106, 191-204.	1.2	222
481	Biobanking of CSF: International standardization to optimize biomarker development. <i>Clinical Biochemistry</i> , 2014, 47, 288-292.	0.8	97
482	The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. <i>Alzheimer's and Dementia</i> , 2014, 10, 808-817.	0.4	163
483	The association of angiotensin-converting enzyme with biomarkers for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 27.	3.0	63
484	Brain network alterations in Alzheimer's disease measured by Eigenvector centrality in fMRI are related to cognition and CSF biomarkers. <i>Human Brain Mapping</i> , 2014, 35, 2383-2393.	1.9	108
485	Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. <i>Neurology</i> , 2014, 83, 1210-1216.	1.5	30
486	BRI2-BRICHOS is increased in human amyloid plaques in early stages of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 1596-1604.	1.5	46

#	ARTICLE	IF	CITATIONS
487	Cerebrospinal fluid apolipoprotein E and phospholipid transfer protein activity are reduced in multiple sclerosis; relationships with the brain MRI and CSF lipid variables. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 533-541.	0.9	16
488	The cerebrospinal fluid "Alzheimer profile" Easily said, but what does it mean?. <i>Alzheimer's and Dementia</i> , 2014, 10, 713.	0.4	249
489	The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISA. <i>Journal of Immunological Methods</i> , 2014, 402, 43-49.	0.6	57
490	Optimizing Patient Care and Research: The Amsterdam Dementia Cohort. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 313-327.	1.2	307
491	Concordance Between Cerebrospinal Fluid Biomarkers and [11C]PIB PET in a Memory Clinic Cohort. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 801-807.	1.2	109
492	S4-01-04: INTERNATIONAL STANDARDIZATION TO OBTAIN THE BEST POSSIBLE CSF BIOMARKERS. , 2014, 10, P239-P239.		0
493	O5-05-04: MATRIX METALLOPROTEINASES IN RELATION TO ALZHEIMER'S DISEASE AND CAA. , 2014, 10, P300-P300.		0
494	P4-278: IDENTIFICATION OF NOVEL DIAGNOSTIC CSF PROTEIN BIOMARKERS FOR FTD WITH HIGH DISCRIMINATORY POWER. , 2014, 10, P886-P886.		0
495	P4-273: CEREBROSPINAL FLUID NEUROGRANIN AS A PROGNOSTIC MARKER IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE. , 2014, 10, P884-P884.		0
496	Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. <i>Journal of Neuroinflammation</i> , 2013, 10, 35.	3.1	409
497	HPA axis activity in multiple sclerosis correlates with disease severity, lesion type and gene expression in normal-appearing white matter. <i>Acta Neuropathologica</i> , 2013, 126, 237-249.	3.9	66
498	Cerebrospinal fluid and plasma clusterin levels in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 1079-1083.	1.1	26
499	Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and controls using iTRAQ and SID-SRM. <i>Journal of Proteomics</i> , 2013, 78, 312-325.	1.2	58
500	The effectiveness of aerobic training, cognitive behavioural therapy, and energy conservation management in treating MS-related fatigue: the design of the TREFAMS-ACE programme. <i>Trials</i> , 2013, 14, 250.	0.7	41
501	Recent progress in omics-driven analysis of MS to unravel pathological mechanisms. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 1001-1016.	1.4	5
502	CSF biomarker variability in the Alzheimer's Association quality control program. <i>Alzheimer's and Dementia</i> , 2013, 9, 251-261.	0.4	344
503	O1-09-01: Diagnostic impact of CSF biomarkers for Alzheimer's disease in a memory clinic setting. , 2013, 9, P144-P145.		0
504	Cerebrospinal fluid A β 242 is the best predictor of clinical progression in patients with subjective complaints. <i>Alzheimer's and Dementia</i> , 2013, 9, 481-487.	0.4	164

#	ARTICLE	IF	CITATIONS
505	Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study. <i>Alzheimer's and Dementia</i> , 2013, 9, 276-283.	0.4	25
506	Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. <i>Neurology</i> , 2013, 80, 1048-1056.	1.5	161
507	Preclinical AD predicts decline in memory and executive functions in subjective complaints. <i>Neurology</i> , 2013, 81, 1409-1416.	1.5	122
508	CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2013, 19, 436-442.	1.4	70
509	Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1802-1809.	1.4	133
510	Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS – Neurofilament as a Surrogate of Disease Progression. <i>PLoS ONE</i> , 2013, 8, e70019.	1.1	48
511	Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1092-1098.	1.4	16
512	Injury markers predict time to dementia in subjects with MCI and amyloid pathology. <i>Neurology</i> , 2012, 79, 1809-1816.	1.5	129
513	Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. <i>Neurology</i> , 2012, 78, 47-54.	1.5	255
514	Injury Markers but not Amyloid Markers are Associated with Rapid Progression from Mild Cognitive Impairment to Dementia in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 29, 319-327.	1.2	73
515	Neurofilaments as biomarkers in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 552-556.	1.4	195
516	Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases. <i>Methods</i> , 2012, 56, 508-513.	1.9	38
517	Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. <i>Alzheimer's and Dementia</i> , 2012, 8, 65-73.	0.4	271
518	Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2012, 13, 1-10.	2.3	81
519	Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers. <i>Neurobiology of Aging</i> , 2012, 33, 1591-1598.	1.5	52
520	Microbleeds relate to altered amyloid-beta metabolism in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 1011.e1-1011.e9.	1.5	55
521	Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. <i>Biomarkers in Medicine</i> , 2012, 6, 419-430.	0.6	280
522	Cerebrospinal fluid anti-whole myelin antibodies are not correlated to magnetic resonance imaging activity in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2012, 251, 103-106.	1.1	2

#	ARTICLE	IF	CITATIONS
523	Neurofilament stoichiometry simulations during neurodegeneration suggest a remarkable self-sufficient and stable in vivo protein structure. <i>Journal of the Neurological Sciences</i> , 2011, 307, 132-138.	0.3	17
524	Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry. <i>Multiple Sclerosis Journal</i> , 2011, 17, 838-850.	1.4	46
525	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. <i>Alzheimer's and Dementia</i> , 2011, 7, 386.	0.4	354
526	Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies. <i>Multiple Sclerosis International</i> , 2011, 2011, 1-9.	0.4	52
527	Brain-specific fatty acid-binding protein is elevated in serum of patients with dementia-related diseases. <i>European Journal of Neurology</i> , 2011, 18, 865-871.	1.7	51
528	The neurofilament light chain is not stable in vitro. <i>Annals of Neurology</i> , 2011, 69, 1065-1066.	2.8	23
529	Neurofilament ELISA validation. <i>Journal of Immunological Methods</i> , 2010, 352, 23-31.	0.6	86
530	Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: A pathogenetically based approach. <i>Neurobiology of Disease</i> , 2010, 39, 229-241.	2.1	67
531	Batch prepared protein standards for cerebrospinal fluid (CSF) biomarkers for neurodegeneration. <i>Journal of Neuroscience Methods</i> , 2010, 193, 296-299.	1.3	5
532	Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid β , Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop. <i>International Journal of Alzheimer's Disease</i> , 2010, 2010, 1-6.	1.1	50
533	cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases. <i>International Journal of Alzheimer's Disease</i> , 2010, 2010, 1-12.	1.1	16
534	Short commentary on "a consensus protocol for the standardization of cerebrospinal fluid collection and biobanking". <i>Multiple Sclerosis Journal</i> , 2010, 16, 129-132.	1.4	7
535	Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency. <i>Neurology</i> , 2010, 75, 1617-1622.	1.5	54
536	Konsensusprotokoll zur Standardisierung von Entnahme und Biobanking des Liquor cerebrospinalis / A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking. <i>Laboratoriums Medizin</i> , 2010, 34, 1-12.	0.1	3
537	Combination of CSF <i>N</i> -acetylaspartate and neurofilaments in multiple sclerosis. <i>Neurology</i> , 2009, 72, 1322-1329.	1.5	189
538	A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. <i>Neurology</i> , 2009, 73, 1914-1922.	1.5	653
539	EFNS guidelines on disease-specific CSF investigations. <i>European Journal of Neurology</i> , 2009, 16, 760.	1.7	73
540	Serum homocysteine levels in relation to clinical progression in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 1349-1353.	0.9	46

#	ARTICLE	IF	CITATIONS
541	Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases. <i>Expert Review of Molecular Diagnostics</i> , 2008, 8, 479-494.	1.5	77
542	Biomarker research in multiple sclerosis: addressing axonal damage and heterogeneity. <i>Biomarkers in Medicine</i> , 2007, 1, 111-119.	0.6	8
543	CSF Neurofilaments in Frontotemporal Dementia Compared with Early Onset Alzheimer's Disease and Controls. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 225-230.	0.7	64
544	24S-hydroxycholesterol in relation to disease manifestations of acute experimental autoimmune encephalomyelitis. <i>Journal of Neuroscience Research</i> , 2007, 85, 1499-1505.	1.3	45
545	Endogeneous peptide profiling of cerebrospinal fluid by MALDI-TOF mass spectrometry: Optimization of magnetic bead-based peptide capture and analysis of preanalytical variables. <i>Proteomics - Clinical Applications</i> , 2007, 1, 1385-1392.	0.8	35
546	Proteolytic shedding of the macrophage scavenger receptor CD163 in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2007, 187, 179-186.	1.1	51
547	N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry. <i>Journal of Neurology</i> , 2007, 254, 631-637.	1.8	39
548	Growth-associated protein 43 in lesions and cerebrospinal fluid in multiple sclerosis. <i>Neuropathology and Applied Neurobiology</i> , 2006, 32, 318-331.	1.8	22
549	Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. <i>Lancet Neurology</i> , The, 2005, 4, 32-41.	4.9	230
550	In vivo detection of myelin proteins in cervical lymph nodes of MS patients using ultrasound-guided fine-needle aspiration cytology. <i>Journal of Neuroimmunology</i> , 2005, 161, 190-194.	1.1	90
551	Homocysteine in relation to cognitive performance in pathological and non-pathological conditions. <i>Clinical Chemistry and Laboratory Medicine</i> , 2005, 43, 1089-95.	1.4	26
552	Biomarkers for Alzheimer's disease. Which way to go?. <i>Neurobiology of Aging</i> , 2004, 25, 695-696.	1.5	5
553	Inflammation markers in relation to cognition in a healthy aging population. <i>Journal of Neuroimmunology</i> , 2003, 134, 142-150.	1.1	250
554	Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients. <i>Neuroscience Letters</i> , 2003, 347, 159-162.	1.0	92
555	Combination of serum markers related to several mechanisms in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2003, 24, 893-902.	1.5	85
556	Homocysteine: a marker for cognitive performance? A longitudinal follow-up study. <i>Journal of Nutrition, Health and Aging</i> , 2003, 7, 153-9.	1.5	52
557	Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. <i>Neurobiology of Aging</i> , 2002, 23, 485-508.	1.5	173
558	STABILITY OF INTERLEUKIN 6, SOLUBLE INTERLEUKIN 6 RECEPTOR, INTERLEUKIN 10 AND CC16 IN HUMAN SERUM. <i>Cytokine</i> , 2002, 19, 228-235.	1.4	92

#	ARTICLE	IF	CITATIONS
559	Evaluation of 3-nitrotyrosine as a marker for 3-nitropropionic acid-induced oxidative stress in Lewis and Wistar rats and strain-specific whole brain spheroid cultures. <i>Brain Research</i> , 2002, 931, 5-20.	1.1	20
560	Stability of interleukin 6, soluble interleukin 6 receptor, interleukin 10 and CC16 in human serum. <i>Cytokine</i> , 2002, 19, 228-35.	1.4	38
561	Behavioural correlates of striatal glial fibrillary acidic protein in the 3-nitropropionic acid rat model: disturbed walking pattern and spatial orientation. <i>Neuroscience</i> , 2001, 105, 153-167.	1.1	58
562	Concentrations of different sterols in the striatum and serum of 3-nitropropionic acid-treated Wistar and Lewis rats. <i>Neurochemical Research</i> , 2001, 26, 1237-1244.	1.6	10
563	Whole brain spheroid cultures as a model to study the development of nitric oxide synthase-guanylate cyclase signal transduction. <i>Developmental Brain Research</i> , 2000, 125, 99-115.	2.1	16
564	Multi-Omics Interdisciplinary Research Integration to Accelerate Dementia Biomarker Development (MIRIADe). <i>Frontiers in Neurology</i> , 0, 13, .	1.1	10